Trevi Therapeutics Inc., headquartered in New Haven, has enrolled the first patient in a pivotal study of Nalbuphine ER in hemodialysis patients with uremic pruritus.

“There has been a significant amount of research done over a number of years hypothesizing that the mu antagonist/kappa agonist mechanism could be a good treatment option for patients suffering from chronic pruritus,” said  Thomas R. Sciascia, M.D., Trevi’s Chief Medical Officer. “This study is an important step in advancing the research that has been done around the world in chronic pruritus.”